May 4, 2023 07:16 AM EDTUpdated 07:33 AM
R&D
Pharma

Val­ne­va, Pfiz­er de­lay their Ly­me dis­ease vac­cine sub­mis­sion to 2026

Kyle LaHucik

Senior Reporter

Val­ne­va said Pfiz­er now aims to sub­mit their part­nered Ly­me dis­ease vac­cine can­di­date to US and Eu­ro­pean reg­u­la­tors in 2026, rather than 2025, pend­ing Phase …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

A service from the Financial Times